Towards Personalized Dosing of Natalizumab in Multiple Sclerosis

PHASE4CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

November 3, 2016

Primary Completion Date

June 21, 2019

Study Completion Date

July 1, 2019

Conditions
Multiple Sclerosis
Interventions
DRUG

Natalizumab

Extending dose intervals of natalizumab from 4 weeks to maximum of 8 weeks based on trough natalizumab concentrations

Trial Locations (5)

Unknown

OLVG, Amsterdam

VU medical center, Amsterdam

Rijnstate Hospital, Arnhem

Erasmus medical center, Rotterdam

St. Antonius Hospital, Utrecht

All Listed Sponsors
collaborator

Prothya Biosolutions

INDUSTRY

collaborator

Erasmus Medical Center

OTHER

collaborator

St. Antonius Hospital

OTHER

collaborator

OLVG

NETWORK

collaborator

Rijnstate Hospital

OTHER

lead

Amsterdam UMC, location VUmc

OTHER

NCT03516526 - Towards Personalized Dosing of Natalizumab in Multiple Sclerosis | Biotech Hunter | Biotech Hunter